Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study is being done to analyze the safety, tolerability, and efficacy of treatment using
combination of Pegylated Interferon Alfa-2b and anti-PD-1/PD-L1 antibodies for patients with
advanced hepatocellular carcinoma.